High-risk Myelodysplastic Syndromes

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies [Phase 1, Phase 2]

  Phase 1/Phase 2 clinical trial evaluating adaptive dual-target CAR-T cell therapy for relapsed or refractory hematologic malignancies; recru…

• CLINICAL_TRIALS trial_result · 2022-11-10
  Clinical Trial Update: GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies [Phase 1, Phase 2]

  Phase 1/2 trial of GTB-3550 Tri-Specific Killer Engager (TriKE) for high-risk hematologic malignancies has been terminated; results posted i…